| Cobimetinib | None | ||
| 20MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| COTELLIC® is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. | |||
|
Yes
| |||
| Cotellic | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | |||||||||||||
| ********** ** *** ********** *** *** ********* ** ************* ******** | ********** ** *** ********** *** *** ********* ** ************* ******** | ********** ** *** ********** *** *** ********* ** ************* ******** | ********** ** *** ********** *** *** ********* ** ************* ******** | *********-******* ******* ********** ************ *** ******* ** ****** *** ***** *** **** | *********-******* ******* ********** ************ *** ******* ** ****** *** ***** *** **** | *********** ******** **** ** (*)-[*,*-********-*-(*-******-*-***************)******] [*-*******-*-(*********-*-**) ********-*-**]********* | *********** ******** **** ** (*)-[*,*-********-*-(*-******-*-***************)******] [*-*******-*-(*********-*-**) ********-*-**]********* | *********** ********* | *********** ********* | *********** ******** **** ** (*)-[*,*-********-*-(*-******-*-***************)******] [*-*******-*-(*********-*-**) ********-*-**]-********* | *********** ******** **** ** (*)-[*,*-********-*-(*-******-*-***************)******] [*-*******-*-(*********-*-**) ********-*-**]-********* | *** ********** *** ******* ** ***** *** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|